1-2 of 2
Wei Dong Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz
Journal: Blood
Blood (2023) 142 (Supplement 1): 6737.
https://doi.org/10.1182/blood-2023-189700
Published: 2023
Journal Articles

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Alexander Lesokhin, Shinsuke Iida, Don Stevens, Afshin Eli Gabayan, Wei Dong Ma, Sharon Sullivan, Marc-Steffen Raab
Journal: Blood
Blood (2021) 138 (Supplement 1): 1674.
https://doi.org/10.1182/blood-2021-152984
Published: 2021